AEP
59
-3
IFF
60
-3
KMI
59
2
VRTX
56
-4
HRL
38
2
MAR
50
3
HBI
59
-2
ADSK
65
-2
SPG
53
-2
CMCSA
52
6
CRM
50
-5
FTI
69
-7
GRMN
50
-2
SYY
50
-8
AIG
51
-2
TGT
50
2
MS
50
-8
GD
57
-2
MCHP
42
-5
QRVO
33
-3
AEP
59
-3
IFF
60
-3
KMI
59
2
VRTX
56
-4
HRL
38
2
MAR
50
3
HBI
59
-2
ADSK
65
-2
SPG
53
-2
CMCSA
52
6
CRM
50
-5
FTI
69
-7
GRMN
50
-2
SYY
50
-8
AIG
51
-2
TGT
50
2
MS
50
-8
GD
57
-2
MCHP
42
-5
QRVO
33
-3
Financhill
Back

Halozyme Therapeutics Stock Predictions

How to Profit From "America's Earnings" Reports

New Trade Goes LIVE THIS TUESDAY at 2 pm
Buy
60

HALO
Halozyme Therapeutics

Last Price:
59.37
Seasonality Move:
10.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Hint at where the next big move in the market will be this month

Spot the next big move with this free book from a hedge fund manager

Halozyme Therapeutics Stock Forecast

  • Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 28.3% based on the past 20 years of stock performance.
  • Halozyme Therapeutics has risen higher in 12 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%
  • Is Halozyme Therapeutics Stock Undervalued?
    The current Halozyme Therapeutics [HALO] share price is $62.31. The Score for HALO is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
  • HALO is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.

Will Halozyme Therapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, Halozyme Therapeutics has on average historically risen by 28.3% based on the past 20 years of stock performance.

Halozyme Therapeutics Stock Rating

Buy
60
Halozyme Therapeutics (HALO) is a Buy

Is Halozyme Therapeutics overpriced?

  • Halozyme Therapeutics has risen higher in 12 of those 20 years over the subsequent 52-week period, corresponding to a historical accuracy of 60%

Halozyme Therapeutics Stock Price History

Is HALO stock going to rise?

  • The current trend is moderately bearish and HALO is experiencing slight selling pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
halozyme.com

52-Week Data

52-Week High:
65.53
52-Week Low:
32.83

Prediction Charts

Market Cap:
7.89B
Price in USD:
62.31
Volume:
1.18M
Beta:
1.48

Technical Analysis

SMA50:
57.93
SMA100:
52.25
SMA200:
45.18
52-Wk Change:
59.32%

Stock Predictions

  • Is Halozyme Therapeutics stock public?
    Yes, Halozyme Therapeutics is a publicly traded company.
  • What is the Halozyme Therapeutics stock quote today?
    The Halozyme Therapeutics stock price is 62.31 USD today.
  • How to buy Halozyme Therapeutics stock online?
    You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Aug-29 64.98 63.74 65.53 63.60
Aug-30 63.76 63.82 64.30 63.23
Sep-3 63.59 61.23 64.18 61.05
Sep-4 61.00 62.13 62.20 60.82
Sep-5 62.50 61.09 62.81 60.45
Sep-6 61.25 59.21 61.64 58.94
Sep-9 59.95 59.23 59.95 58.81
Sep-10 59.23 59.26 59.84 58.59
Sep-11 59.01 59.39 60.14 58.64
Sep-12 59.43 60.55 61.34 58.91
Sep-13 61.02 62.30 62.93 61.00
Sep-16 62.78 62.91 63.45 62.56
Sep-17 62.91 61.93 63.28 61.25
Sep-18 61.93 62.31 63.50 61.30

Halozyme Therapeutics Earnings

Halozyme Therapeutics Earnings Report: Per Share Halozyme Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

Halozyme Therapeutics Forecast Revenue Growth

Halozyme Therapeutics Stock Analysis: Historical quarterly revenues per share for Halozyme Therapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.30 per share, an increase next quarter of $0.25 per share, an increase this year of $1.19 per share, and an increase next year of $0.84 per share.

* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.